FDA Defends AD Drug Approval, Others Say It ' s a ' 9/11 Moment ' FDA Defends AD Drug Approval, Others Say It ' s a ' 9/11 Moment '

FDA leaders defend their okay of aducanumab for AD, saying the drug fits with the accelerated approval pathway; others say the decision speaks to the need to reform the pathway.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news